人类试验 Human trials
左右滑动查看Swipe to see more
| 更新日期 Updated |
项目简介 Project |
状态 Status |
最新进展 Latest |
证据 Evidence |
|---|---|---|---|---|
| 2026-10-08 | Life Bio ER-100:眼部 OSK 表观重编程基因治疗(玻璃体腔给药) Life Bio ER-100: ocular OSK epigenetic reprogramming gene therapy (intravitreal) Life Bio · NCT07290244 |
I 期 / Phase 1 | 中期:3 人至 Day56 无严重不良事件,建议升剂量;2 人视野有初步信号 Interim: 3 pts to Day56 no SAE; DSMB escalate; 2 with early visual-field signals |
公司中期披露 / company interim |
| 2026-10-08 | XPRIZE · RPRGAON-Progeria:韩国小分子 Progerinin,清 progerin XPRIZE · RPRGAON-Progeria: Progerinin small molecule designed to clear progerin XPRIZE |
Milestone 2 | 健康人 I 期已完成;儿童 HGPS II 期(BCH)与密歇根成体 Werner II 期已开招 Healthy Phase 1 done; pediatric HGPS Phase 2 (BCH) and Michigan adult Werner Phase 2 recruiting |
Asiae + NCT04512963 / NCT06775041 / NCT05847179 |
| 2026-09-21 | Retro RTR242:口服液,健康人 SAD/MAD I 期(溶酶体再酸化;登记适应症栏早发型阿尔茨海默,非患者入组) Retro RTR242: oral liquid, healthy SAD/MAD Phase 1 (lysosomal re-acidification; registry indication early AD, no patients enrolled) Retro · ACTRN12625001274460 |
I 期 / Phase 1 | 澳大利亚扩剂量中;健康人 SAD/MAD,适应症栏为早发型阿尔茨海默 Dose escalation in Australia; healthy volunteers; indication field early-onset AD |
ANZCTR |
| 2026-09-10 | 英矽智能 Rentosertib:中国 IPF · TNIK 抑制剂 Insilico Rentosertib: China IPF · TNIK inhibitor Insilico |
III 期 / Phase 3 | GENESIS-IPF-3 首例给药;约 47 中心 / 约 320 人;主终点 52 周 FVC First patient dosed in GENESIS-IPF-3; ~47 sites / ~320 pts; primary endpoint 52-wk FVC |
公司稿 + 登记 / company + registry |
| 2026-09-10 | XPRIZE · Longeveron:异体骨髓间充质干细胞 laromestrocel XPRIZE · Longeveron: allogeneic MSC laromestrocel Longeveron |
Milestone 2 | 既往衰弱 IIb 6 分钟步行较安慰剂改善;决赛将测肌肉/认知/免疫,预计 2027 夏开招 Prior frailty IIb 6MWT vs placebo improved; finalist endpoints muscle/cognition/immunity; ~summer 2027 enroll |
Cell Stem Cell |
| 2026-09-01 | BioViva:Klotho + hTERT 基因治疗专利路径 BioViva: Klotho + hTERT gene-therapy patent path BioViva |
专利 / Patent | 美国专利覆盖年龄相关认知下降的基因递送方法 US patent covers gene delivery for age-related cognitive decline |
专利公告 / patent notice |
| 2026-08-20 | XPRIZE · TIME TRAVELER:日本欧芹植物 EV 口服胶囊 XPRIZE · TIME TRAVELER: Japanese parsley plant-EV oral capsules 报道页 / report |
Milestone 2 | 日本双盲安慰剂 8 周(UMIN000059942,约 55-69 岁);数值结果未公开 Japan DBPC 8-wk (UMIN000059942, ~55-69y); numerical results not public |
UMIN |
| 2026-08-19 | Moderna/默沙东 intismeran:黑色素瘤个体化 mRNA 新抗原疗法 Moderna/MSD intismeran: personalized melanoma mRNA neoantigen therapy Moderna |
III 期读出 / Phase 3 readout | INTerpath-001:RFS、DMFS 优于单用帕博利珠单抗(约 1137 人;中期 topline,HR 未披露) INTerpath-001: RFS & DMFS better than pembrolizumab alone (~1137; interim topline, HR not disclosed) |
公司 topline / company topline |
| 2026-08-17 | XPRIZE · Goda Lab:稀土改造「超级外泌体」靶向衰老细胞 XPRIZE · Goda Lab: rare-earth engineered 'super-exosomes' targeting senescent cells 东京大学 / UTokyo |
Milestone 2 | 小鼠改善衰弱与体能;与东北大学医院筹备人体试验 Mouse frailty/physical gains; preparing human trial with Tohoku Univ Hospital |
大学新闻 / univ news |
| 2026-08-13 | XPRIZE · RETRO-EPIGERNA:澳门 KYN 复合胶囊(中药 + 益生菌) XPRIZE · RETRO-EPIGERNA: Macao KYN capsule (TCM + probiotics) 澳科大 / MUST |
Milestone 2 | 靶向衰老相关 tRNA 修饰;半决赛小样本人体已做,配方未公开 Targets aging-related tRNA modification; small semi-final human study done; formula undisclosed |
澳科大 / MUST |
| 2026-08-11 | XPRIZE · AgelessRx:远程 9 联药 + 抗阻与教练 XPRIZE · AgelessRx: remote 9-drug stack + resistance training & coaching AgelessRx |
Milestone 2 | 雷帕霉素、二甲双胍、纳曲酮、NAD、Tirzepatide 等;决赛约 235 人、双盲 12 个月 Rapamycin, metformin, naltrexone, NAD, Tirzepatide, etc.; ~235 DBPC 12 mo |
AgelessRx + NCT |
| 2026-08-11 | XPRIZE · Johns Hopkins-Suninflam:抗 Galectin-3 单抗 SIF001 XPRIZE · Johns Hopkins-Suninflam: anti-Galectin-3 mAb SIF001 JH CAIR |
Milestone 2 | 当前 I 期剂量爬坡(NCT07051629);健康长寿决赛细节未公开 Phase 1 dose escalation (NCT07051629); healthspan finalist details not public |
JH + NCT |
| 2026-08-11 | XPRIZE · Minicircle:FST + Klotho 非病毒质粒腹脂注射 XPRIZE · Minicircle: FST + Klotho non-viral plasmid (abdominal fat) Minicircle |
Milestone 2 | 联合小样本试点(NCT07285629)已完成,公开疗效数字仍少 Combo small pilot (NCT07285629) completed; public efficacy numbers still scarce |
NCT |
| 2026-08-11 | XPRIZE · Mitochondrial All Stars:elamipretide(SS-31)稳线粒体 XPRIZE · Mitochondrial All Stars: elamipretide (SS-31) mitochondrial stabilizer Mighty/UW |
Milestone 2 | 老年皮下试点后准备双盲安慰剂 RCT After elderly SC pilot, preparing DBPC RCT |
PR + NCT |
| 2026-08-11 | XPRIZE · NYC-Vita:雷帕霉素/拉米夫定 + 亚精胺 + 有监督运动 XPRIZE · NYC-Vita: rapamycin/lamivudine + spermidine + supervised exercise Mount Sinai |
Milestone 2 | 半决赛小试验已完成;扩展试验预计 2026 年底前后开招 Semi-final small study done; expanded trial ~late 2026 enroll |
Sinai + NCT |
| 2026-08-01 | BioNTech BNT168:HIV RNA 疫苗(阴性与阳性受试者,含分析性停药探索) BioNTech BNT168: HIV RNA vaccine (negatives & PLWH, includes ATI exploration) NCT07698600 |
I 期 / Phase 1 | 美/南非招募中;尚无免疫原性或效力读出 US/South Africa recruiting; no immunogenicity or efficacy readout yet |
CT.gov |
| 2026-06-02 | NewLimit:肝细胞表观重编程平台 NewLimit: hepatocyte epigenetic reprogramming platform NewLimit |
临床前 / Preclinical | 约 4.35 亿美元 C 轮;计划 2027 年人体试验 ~$435M Series C; plans 2027 first-in-human |
融资公告 / financing |
| 2026-05-22 | Retro 其余管线:iPSC 细胞与组织重编程等 Retro other pipeline: iPSC cell & tissue reprogramming, etc. Retro Science |
临床前 / Preclinical | 公开信息仍为临床前;人体登记以 RTR242 为准 Still publicly preclinical; human registry is RTR242 |
公司公开页 / company page |
| 2026-03-30 | R3 Bio:无脑克隆 / 全身替换愿景 R3 Bio: brainless clone / whole-body replacement vision R3 Bio |
未证实 / Unverified | 媒体报道投资者路演愿景;公司称当前做细胞培养级平台 Media covers investor-pitch vision; company says current work is culture-scale platform |
调查报道 / investigative press |
| 2026-01-06 | IAVI G004 / Moderna mRNA-1645:HIV germline 靶向(eOD + Core + N332-GT5) IAVI G004 / Moderna mRNA-1645: HIV germline targeting (eOD + Core + N332-GT5) NCT06694753 |
I 期 / Phase 1 | 2025-12 首剂;低剂量设计减皮肤反应;尚无公开读出 First dose Dec 2025; low-dose to cut skin AEs; no public readout yet |
IAVI + CT.gov |
| 2025-11-19 | 辉瑞季节性流感 modRNA 疫苗 Pfizer seasonal influenza modRNA vaccine NEJM |
III 期发表 / Phase 3 published | 18-64 岁相对效力约 34.5% vs 灭活四价 Ages 18-64 relative efficacy ~34.5% vs inactivated QIV |
同行评审 / peer-reviewed |
| 2025-10-16 | 威斯津 WGc-0201:慢性乙肝治疗性 LNP-mRNA(华西) WestGene WGc-0201: therapeutic LNP-mRNA for chronic HBV (West China) NCT07051187 |
I 期 / Phase 1 | 剂量爬坡招募中;目标功能治愈,尚无人体疗效读出 Dose escalation recruiting; functional cure is design goal; no human efficacy readout yet |
CT.gov |
| 2025-10-09 | Altos Labs:表观重编程与体外器官灌注平台 Altos Labs: epigenetic reprogramming & ex vivo organ perfusion platform Altos |
临床前 / Preclinical | 体外器官上测试部分重编程等;尚无公开人体试验 Testing partial reprogramming on ex vivo organs; no public human trial yet |
行业媒体 / trade press |
| 2025-09-01 | 威斯津 WGc-0201:HBV 相关晚期肝癌治疗性 mRNA WestGene WGc-0201: therapeutic mRNA for HBV-related advanced HCC NCT05738447 |
I 期 / Phase 1 | n=12 无 DLT;可评估 10 人 DCR 约 70%,中位 PFS 2.6 月(ESMO 2025;开标 I 期探索终点,非确证效力) n=12 no DLT; evaluable n=10 DCR ~70%, mPFS 2.6 mo (ESMO 2025; open-label Phase 1 exploratory, not confirmatory efficacy) |
ESMO 摘要 / ESMO abstract |
| 2025-07-31 | IAVI/Moderna mRNA-1644:HIV eOD-GT8 germline 靶向(G002/G003) IAVI/Moderna mRNA-1644: HIV eOD-GT8 germline targeting (G002/G003) Science |
I 期读出 / Phase 1 readout | 约 94% 诱导 VRC01 类 bnAb 前体;皮肤 AE 约 18%、荨麻疹约 12%;无感染保护终点 ~94% induced VRC01-class bnAb precursors; skin AE ~18%, urticaria ~12%; no infection-prevention endpoint |
Science 2025 |
| 2025-01-01 | HVTN 302:HIV BG505 三聚体 mRNA(Moderna 代工) HVTN 302: HIV BG505 trimer mRNA (Moderna-manufactured) Sci Transl Med |
I 期读出 / Phase 1 readout | 膜锚定三聚体约 80% 产生自体 tier-2 中和 Ab;荨麻疹约 7%;无现场效力 Membrane-anchored trimer ~80% autologous tier-2 nAb; urticaria ~7%; no field efficacy |
Sci Transl Med |
动物实验 Animal studies
首批方向:部分重编程 + 衰老细胞清除 First tracks: partial reprogramming + senolytics
左右滑动查看Swipe to see more
| 更新日期 Updated |
项目简介 Project |
状态 Status |
最新进展 Latest |
证据 Evidence |
|---|---|---|---|---|
| 2026-07-01 | 长期 D+Q 对自然衰老小鼠肾脏的多组学评估 Long-term D+Q multi-omics of naturally aged mouse kidney npj Regen Med |
衰老细胞清除 / Senolytic | 降低 p16/p21 与纤维化炎症,恢复 Klotho,重塑肾小管通讯与脂质代谢 Lowered p16/p21 and fibro-inflammation; restored Klotho; remodeled tubular communication & lipid metabolism |
npj Regenerative Medicine |
| 2026-06-17 | 老年小鼠多组织单细胞图谱解析 D+Q 疗效与干预时机 Aged-mouse multi-tissue scRNA atlas of D+Q efficacy and timing Nature Aging |
衰老细胞清除 / Senolytic | 免疫、纤维化与代谢读数改善;早启动、长疗程优于晚而短的干预 Immune, fibrosis & metabolic readouts improved; early/long beats late/short |
Nature Aging |
| 2026-02-10 | EPFL:OSK 基因治疗靶向记忆痕迹神经元做部分重编程 EPFL: OSK gene therapy targeting engram neurons for partial reprogramming Neuron |
部分重编程 / Partial reprogramming | 老年与阿尔茨海默模型小鼠学习记忆显著改善,接近年轻对照;纠正突触可塑性相关表观转录异常 Aged & AD-model mice: learning/memory markedly improved, near young controls; corrected synaptic plasticity epi-transcriptomic deficits |
Neuron |
| 2026-01-27 | 化学鸡尾酒 7c 在 UM-HET3 小鼠的体内部分重编程安全性 Chemical cocktail 7c in vivo partial-reprogramming safety in UM-HET3 mice Aging Cell |
部分重编程 / Partial reprogramming | 安全剂量未降肝肾转录组年龄;高剂量致体重骤降、脂滴堆积与线粒体应激 Safe dose did not lower liver/kidney transcriptomic age; high dose caused weight drop, lipid droplets & mito stress |
Aging Cell |
| 2024-09-11 | Altos/Belmonte:Cdkn2a 启动子驱动 OSK,仅重编程衰老/应激细胞 Altos/Belmonte: Cdkn2a-driven OSK reprogramming only senescent/stressed cells Sci Transl Med |
部分重编程 / Partial reprogramming | 早衰与自然衰老小鼠延寿、炎症下降、伤口愈合改善,肿瘤发生率未见升高 Progeria & naturally aged mice: lifespan↑, inflammation↓, wound healing↑; no rise in tumor incidence |
Science Translational Medicine |
| 2022-03-07 | Salk 等:长期周期 OSKM 部分重编程作用于生理衰老小鼠 Salk et al.: cyclic long-term OSKM partial reprogramming in physiologically aged mice Nature Aging |
部分重编程 / Partial reprogramming | 肾、皮肤等多组织年轻化,表观时钟回拨;疗程越长获益越大 Multi-tissue rejuvenation (kidney, skin, etc.); epigenetic clocks rewind; longer cycles, larger gains |
Nature Aging |
| 2020-12-02 | Sinclair:AAV2-OSK 玻璃体腔递送恢复视网膜年轻表观信息(ER-100 临床前根基) Sinclair: AAV2-OSK intravitreal restoration of youthful retinal epigenetic information (ER-100 preclinical basis) Nature |
部分重编程 / Partial reprogramming | 青光眼与老年小鼠视功能改善,视神经轴突可再生,长期表达未见视网膜肿瘤 Glaucoma & aged mice: vision improved, optic axons regenerable; long-term expression no retinal tumors seen |
Nature |
| 2018-07-09 | Mayo Clinic:间歇口服 D+Q 用于自然衰老小鼠体能与生存 Mayo Clinic: intermittent oral D+Q for fitness & survival in naturally aged mice Nature Medicine |
衰老细胞清除 / Senolytic | 改善体能;24-27 月龄起治可使治疗后生存期延长约 36% Improved fitness; starting at 24-27 mo extended post-treatment survival ~36% |
Nature Medicine |
| 2015-03-09 | 首次系统筛选达沙替尼+槲皮素(D+Q)为选择性清除衰老细胞组合 First systematic screen identifying dasatinib+quercetin (D+Q) as selective senolytic combo Aging Cell |
衰老细胞清除 / Senolytic | 老年小鼠体内衰老标志下降,奠定后续 D+Q 动物与人体试验基础 Lowered senescence markers in aged mice; foundation for later D+Q animal & human trials |
Aging Cell |